Future Cancer: NICE medicines appraisal (Enhertu)

Health and Social Care Committee Closed Non-inquiry session
Opened: 30 Apr 2024 Closed: 30 May 2024 Parliament page
The committee will consider the impact of changes made by NICE to evaluate drugs used to treat patients with terminal illness like cancer in this session. The Future Cancer inquiry received evidence from drugs’ companies that changes by NICE in 2022 on the cost-effectiveness of drugs for severe diseases do … Read more
1 Oral session
2 Letters
1 Event
Activity timeline 4 events
22 May
2024
Correspondence
9 May
2024
Correspondence
8 May
2024
Oral evidence
8 May
2024
Formal meeting (oral evidence session) · Room 8, Palace of Westminster
Oral evidence sessions 1 session
8 May 2024
View on parliament.uk
Baroness Delyth Morgan · Breast Cancer Now David Brocklehurst · AstraZeneca UK Dr Sam Roberts · National Institute for Health and Care Excellence (NICE) Haran Maheson · Daiichi Sankyo UK Helen Knight · National Institute for Health and Care Excellence (NICE)
Correspondence 2 letters
22 May 2024 NICE on Enhertu and the next steps 14.04.24
Parliament page
9 May 2024 Daiichi Sankyo UK & AstraZeneca on HER2-low metastatic breast cancer NICE decision 23.04.24
Parliament page